Germany’s CureVac ditches first-generation COVID jab

The decision comes after final trial results in July confirmed that CureVac’s first vaccine had an efficacy rate of just 48%, well below that of faster rivals Pfizer-BioNTech and Moderna, whose vaccines are based on the same mRNA technology.

Read the full story: Read More